이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

FibroGen 과거 수익 실적

과거 기준 확인 0/6

FibroGen의 수입은 연평균 -25.7%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 12.4%의 비율로 증가했습니다. 매출은 연평균 12.7%의 비율로 감소해 왔습니다.

주요 정보

-25.7%

수익 성장률

-24.0%

EPS 성장률

Biotechs 산업 성장	12.9%
매출 성장률	-12.7%
자기자본 수익률	n/a
순이익	-143.6%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

FibroGen 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BMV:FGEN * 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	167	-240	121
31 Dec 23	148	-284	132
30 Sep 23	155	-294	142
30 Jun 23	131	-322	146
31 Mar 23	116	-307	146
31 Dec 22	141	-294	142
30 Sep 22	123	-362	136
30 Jun 22	263	-220	132
31 Mar 22	258	-281	134
31 Dec 21	235	-290	135
30 Sep 21	284	-215	131
30 Jun 21	172	-231	57
31 Mar 21	190	-183	88
31 Dec 20	176	-189	108
30 Sep 20	119	-229	115
30 Jun 20	108	-311	200
31 Mar 20	257	-110	163
31 Dec 19	257	-77	135
30 Sep 19	357	42	103
30 Jun 19	353	49	82
31 Mar 19	205	-90	70
31 Dec 18	213	-86	64
30 Sep 18	136	-141	60
30 Jun 18	147	-123	57
31 Mar 18	133	-132	56
31 Dec 17	131	-121	52
30 Sep 17	132	-121	50
30 Jun 17	122	-121	49
31 Mar 17	181	-64	46
31 Dec 16	183	-58	46
30 Sep 16	172	-79	46
30 Jun 16	162	-100	46
31 Mar 16	193	-67	45
31 Dec 15	181	-86	44
30 Sep 15	172	-85	44
30 Jun 15	167	-79	43
31 Mar 15	136	-98	41
31 Dec 14	138	-60	37
30 Sep 14	134	-24	32
30 Jun 14	191	43	29
31 Mar 14	117	-5	26
31 Dec 13	102	-15	24

양질의 수익: FGEN * 은(는) 현재 수익성이 없습니다.

이익 마진 증가: FGEN * 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: FGEN * 은(는) 수익성이 없으며 지난 5년 동안 연간 25.7% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 FGEN * 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: FGEN * 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -2.6% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: FGEN * 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

FibroGen 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.81 loss in 1Q 2023)

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

Full year 2023 earnings released: US$2.92 loss per share (vs US$3.14 loss in FY 2022)

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings released: US$0.90 loss per share (vs US$0.78 loss in 2Q 2022)

Recent updates

Senior VP & Chief Medical Officer recently bought Mex$486k worth of stock

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.81 loss in 1Q 2023)

Insufficient new directors

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Insufficient new directors

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

CEO & Director recently bought Mex$1.6m worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings released: US$2.92 loss per share (vs US$3.14 loss in FY 2022)

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Financial position

Insufficient new directors

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Insufficient new directors

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings released: US$0.90 loss per share (vs US$0.78 loss in 2Q 2022)

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Insider recently sold Mex$2.2m worth of stock

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

CEO & Director recently sold Mex$589k worth of stock

CEO & Director recently sold Mex$589k worth of stock

Executive VP & Chief Commercial Officer recently sold Mex$225k worth of stock

Third quarter 2022 earnings released: US$0.98 loss per share (vs US$0.54 profit in 3Q 2021)

FibroGen, Inc. to Report Q3, 2022 Results on Nov 07, 2022

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$1.45 loss in 2Q 2021)

FibroGen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Fibrogen Announces Completion of Patient Enrollment in LELANTOS-2, A Phase 3 Clinical Study of pamrevlumab in Duchenne Muscular Dystrophy

FibroGen, Inc., Annual General Meeting, Jun 16, 2022

FibroGen, Inc. to Report Q1, 2022 Results on May 09, 2022

FibroGen, Inc. Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

FibroGen, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.36 in 3Q 2020)

Independent Director recently sold Mex$3.0m worth of stock

Chief Commercial Officer recently bought Mex$727k worth of stock

FibroGen, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Astellas Receives EC Approval for First-Inclass Evrenzo (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Second quarter 2021 earnings released: US$1.45 loss per share (vs US$0.95 loss in 2Q 2020)

FibroGen, Inc. Announces Outcome of FDA Advisory Committee Review of Roxadustat

Independent Director Kalevi Kurkijärvi has left the company

Astellas Receives Positive CHMP Opinion for Evrenzo™ (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Scott+Scott Attorneys At Law LLP Reminds Investors of Securities Class Action Against Fibrogen, Inc

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.78 loss per share (vs US$0.89 loss in 1Q 2020)

The Schall Law Firm and Roche Freedman LLP Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Fibrogen, Inc

Rosen Law Firm Announces the Filing of a Class Action Lawsuit on Behalf of Purchasers of the Securities of FibroGen, Inc

FibroGen, Inc. Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

Executive Advisor to Chief Executive Officer K. Yu has left the company

Full year 2020 earnings released: US$2.11 loss per share (vs US$0.89 loss in FY 2019)

Revenue misses expectations

FibroGen, Inc. to Report Q4, 2020 Results on Mar 01, 2021

FibroGen, Inc. Enters into Supply Agreement with Astellas Pharma Europe Ltd

FibroGen, Inc. Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2